Pascal Soriot (AP Images)

As­traZeneca plans to spend $535M-plus to ex­pand its R&D net­work and man­u­fac­tur­ing ops in France

UK-based As­traZeneca is steer­ing a sig­nif­i­cant amount of R&D and man­u­fac­tur­ing spend­ing to France,

On the Mon­day hol­i­day, the phar­ma gi­ant made a splash with its French re­lease out­lin­ing plans by CEO Pas­cal So­ri­ot — a na­tive of France — to in­vest $275 mil­lion in ad­di­tion­al R&D part­ner­ing with its grow­ing net­work of French biotech and re­search groups. In par­tic­u­lar, As­traZeneca ex­ecs want to amp up their work in­volv­ing French re­searchers in their glob­al clin­i­cal tri­al net­work.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.